Hypertension is one of the leading causes of all-cause mortality worldwide, and poorly controlled blood pressure is the leading cause of cardiovascular disease (CVD) and cerebrovascular disease. It includes hemorrhagic (58%) and ischemic (50%) stroke, ischemic heart disease (55%), and other forms of CVD (58%), including heart failure and peripheral artery disease [1, 2]. In addition, hypertension is a major cause of dementia caused by chronic kidney disease, renal disease progression, end-stage renal disease, and cerebral microvascular disease [3, 4, 5]. Hypertension includes both essential hypertension and secondary hypertension. Among them, essential hypertension accounts for 90%, and the causes of essential hypertension include genetic factors, living factors, and environmental factors. Living and environmental factors include a high-salt diet, smoking, obesity, and lack of exercise [6, 7]. Recently, studies have shown that genetic factors play a key role in the generation and development of hypertension [8, 9, 10]. Therefore, the study of hypertension gene polymorphisms is of great significance and clinical value.

The renin-angiotensin system (RAS) is one of the most relevant hormone systems for regulating blood volume and blood pressure homeostasis, and is also important in the pathogenesis of cardiovascular and renal diseases. In general, RAS functions as a series of proteolytic enzymes, which successively cleaves the circulating prohormones in the blood to generate the octapeptide angiotensin II (Ang II). Angiotensin II (Ang II) regulates its activity by activating the G protein-coupled angiotensin receptor type 1 (AGTR1) [11].

At the same time, the metabolism of renal energy and substrate may interfere with the regulatory mechanisms of homeostasis, leading to the dysregulation of renal tubular transport and hemodynamics, thus leading to increased blood pressure [12]. The kidney is not only an organ closely related to blood pressure (BP) regulation and the development of hypertension, but also a tissue mediator of the genetic predisposition to hypertension [13]. Chronic kidney disease (CKD) is associated with cardiovascular disease, including hypertension, vascular remodeling, endothelial dysfunction, etc., while angiotensin II (Ang II) is a known channel factor because it may cause pathological changes in blood vessels by mediating structural and functional pathologies, such as abnormal proliferation of vascular smooth muscle and changes in vascular elastin and collagen content [14]. In addition, there have been studies showing that angiotensin II (Ang II) may also mediate vascular effects through inflammation and proteolysis pathways [15], further exacerbating kidney damage. Therefore, angiotensin II (Ang II) is an important factor in the study of the mechanism of action of hypertension complicated by kidney damage, and a series of effects of angiotensin II (Ang II) are mostly produced under the action of angiotensin II receptor 1. Therefore, in the study of hypertension, the AGTR1 gene has been the focus of research. In this paper, the distribution characteristics of the gene polymorphisms of AGTR1 (c.1166 A$>$C) in people with hypertension and hypertension with kidney injury were studied to determine the correlation between AGTR1 gene and hypertension with kidney injury.

The genotype distribution of the combined and hypertensive groups complied with Hardy-Weinberg equilibrium (p $>$ 0.05). Three groups of A GTR1 (c.1166 A$>$C) were distributed statistically significantly (p 0.05), suggesting that hypertension combined with kidney injury and AGTR1 (c.1166 A$>$C) Gene polymorphism is related. The distribution of the A or C allele was not statistically significant (p $>$ 0.05) (Table 2).

The Logistic regression analysis showed that under the co-dominant gene model (AA vs. AC vs. AA), the risk of hypertension with kidney injury was lower than those with AA (OR = 0.877, 95% CI = 0.840–0.915, p = 0.014); those with CC had the greater risk of hypertension with AA (OR = 1.023, 95% CI = 0.978–1.070, p = 0.016). Under the dominant gene model (AA vs. AC + CC), the risk of hypertension combined with kidney injury in those carrying the AA genotype was 5.425-fold higher than in those carrying the AC and CC genotypes (OR = 5.425, 95% CI = 0.767–38.51, p = 0.047). Under the recessive gene model (CC vs. AA + AC), those with CC genotype had a higher risk of hypertension with kidney injury than AA and AC genotypes (OR = 1.023, 95% CI = 0.665–11.067, p = 0.01). The allele type model distribution was not significant (p $>$ 0.05) (Table 3).

Meanwhile, we assessed the relationship between the AGTR1 genotype distribution and other risk factors for cardiovascular disease, for example, hyperlipidemia and diabetes. Among them, defined triglycerides $>$1.7 mmol/L, total cholesterol $>$5.2 mmol/L, HDL cholesterol $>$1.04 mmol/L, LDL cholesterol 3.37 mmol/L were dyslipidemia, and fasting blood glucose higher than 7 mmol/L was diabetes. The results showed that the gene distribution of AGTR1 was not statistically significant (p $>$ 0.05), but was significant with the prevalence of diabetes (p 0.05) (Table 4).

The renin-angiotensin-aldosterone system (RAAS) is a key system for regulating blood volume and blood pressure, and has important implications in the pathogenesis of cardiovascular and renal diseases. Angiotensin is the main active substance of RAAS, which can contract and relax the small systemic blood vessels, which is closely related to the occurrence of hypertension in patients. Secondly, in addition to systemic RAS, there are local renin-angiotensin systems, such as in the kidney, local renin-angiotensin system is different from systemic RAS, the local system through the production of reactive oxygen species, inflammatory factors, vascular response, tissue hypertrophy and fibrosis, which may lead to an increased probability of kidney injury under the pathological state of hypertension. Meanwhile, it was shown that enhanced intracellular angiotensin expression in the high-glucose state led to RAS-induced diabetes development [16], which coincided with the resulting link between AGTR1 gene polymorphism and diabetes development.

The human AGTR1 gene is located at 3 q 21~25, contains only one exon structure, and A1166C is located in the non-coding region at end 3, which does not encode a protein, but may play a role for regulating transcription and translation of genes [17]. From a biological perspective, angiotensin is mainly mediated by A GTR1 and distributed in important tissues and organs such as blood vessels, heart, kidney and other important adults, which has a close impact on hemodynamics [18]. Therefore, the polymorphism expression of the blood, angiotensin receptor 1 gene may be an important factor leading to the range of responses studied above.

Studies have shown that Ang II-induced AT1 receptor signaling (AGTR1) is clinically relevant and diverse in cardiovascular and renal pathology, among which, pharmacological inhibition of RAS, especially inhibition of Ang II formation or Ang II-mediated AT1 activation, has proven to be a very successful strategy for the treatment of multiple cardiovascular and renal diseases [18]. This is consistent with our conclusion that AGTR1 (c.1166 A$>$C) Gene polymorphisms have a certain relationship with the occurrence of kidney injury. At the same time, some scholars have found that the AGTR1 gene is an important predictor of blood pressure response to potassium intake [19]. some scholars have also found that the genetic diversity of AGTR1 is related to hypertension combined with myocardial infarction [20]. Therefore, we believe that AGTR1 plays a crucial role in the occurrence and development of hypertension and kidney injury in hypertension. Therefore, we recommend that hypertensive patients undergo genetic testing to determine the cause and adjust treatment methods when conditions permit. This may avoid damage to other target organs, especially the kidneys, caused by high blood pressure.

Hypertension is already recognized as one of the most important risk factors for cardiovascular disease, and the number of patients with hypertension is very large, however, less than 50% of patients know their hypertension condition, and the rest of the patients who know the condition are not treated or have poor treatment results [21]. Genetic factors play a crucial role in the occurrence and development of hypertension, and multiple genes and susceptibility sites associated with high blood pressure have been found worldwide [22]. In recent years, gene research has provided new ideas and possibilities for the precise treatment of hypertension, and with the completion of the Human Genome Project, the further exploration and development of gene polymorphisms research has brought new hope for the comprehensive treatment of hypertension. This study has some limitations. First, this study was conducted in a relatively small sample, and further validation requires a larger sample size. Secondly, all the patients in this study were from Suzhou Dushu Lake Hospital, so there were certain regional clustering and ethnic unity. Third, despite our rigorous experimental design to reduce possible errors in the study, the inherent bias in the study cannot be excluded from the study.

In conclusion, by exploring the relationship between AGTR1 and hypertension combined with renal injury, we found that AGTR1 (c.1166 A$>$C) Gene polymorphisms have a certain relationship with the occurrence of kidney injury, which is of certain significance for the screening for kidney injury susceptibility in hypertensive patients. At the same time, the collection of data found that the genetic polymorphism of AGTR1 has some relationship to the incidence of diabetes, but the study of the genetic role has some complexity, and the relationship between AGTR1 and hypertension combined with kidney injury needs further exploration.

All data generated or analysed during this study are included in this published article. The datasets used and/or analysed during the article are available from the corresponding author on reasonable request.

YiyZ and YJ designed the study, performed the research, analyse the data, and wrote the paper. ZH and KL helped analyse the data. YafZ participated in the design of the article, participated in and directed the analysis of the data, and helped write the final version. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work to take public responsibility for appropriate portions of the content and agreed to be accountable for all aspects of the work in ensuring that questions related to its accuracy or integrity.

This study was approved by the Dushu Lake Hospital ethics committee, approval number 220017. All patients gave informed consent and signed the informed consent form.

Not applicable.

This research received no external funding.

The authors declare no conflict of interest.